The ATB-Discover project, led by DEINOVE, IBMM and the LMP of the University of Montpellier, is supported by the European Uni...
30 Giugno 2021 - 05:45PM
The ATB-Discover project, led by DEINOVE, IBMM and the LMP of the
University of Montpellier, is supported by the European Union and
Occitania Region
The ATB-Discover project, led by DEINOVE, IBMM
and the LMP of the University of Montpellier, is supported by the
European Union and Occitania Region
- DEINOVE is
intensifying its collaboration with the Max Mousseron Institute of
Biomolecules (IBMM) and the Physical Measurement Laboratory (LMP)
of the University of Montpellier to accelerate the discovery and
identification of new antimicrobial molecules.
- ATB-Discover aims
to develop innovative analytical approaches based on the use of
Ultra High Resolution Mass Spectrometry.
- The
European Regional Development Fund (FEDER) and the Occitania Region
have granted €560K and €430K, respectively, to the ATB-Discover
project over a 30-month period.
DEINOVE (Euronext Growth Paris : ALDEI), a
French biotech company pioneering the exploration and exploitation
of bacterial biodiversity to address the urgent and global
challenge of antimicrobial resistance, announces its collaboration
with the Max Mousseron Institute of Biomolecules (IBMM) and the
Physical Measurement Laboratory (LMP) of the University of
Montpellier for the co-development of new analytical approaches
based on the use of Ultra High Resolution Mass Spectrometry, over a
30-month period. This project benefits from a €990K funding from
the European Regional Development Fund (FEDER) and the Occitania
Region.
The ATB-Discover partnership research project
was selected in the framework of the call for proposals “Regional
Research and Innovation Platforms” (PRRI), in line with the
regional innovation strategy “Innovative and targeted
therapies”.
ATB-Discover aims to complete and strengthen
DEINOVE’s in-house analytical capabilities. This project is in
total synergy with DEINOVE’s industrial strategy for the
development of new antimicrobials, which was recently supported by
two other independent expert committees (see France Relance1 and
Priority Research Program “Antibiotic Resistance”2 press
releases).
ATB-Discover also contributes to the territorial
policy by federating a scientific, institutional and economic
community committed to the societal challenges of MUSE “Montpellier
University of Excellence: Nourish/Care/Protect”3. This innovative
collaborative research project relies on a vast range of techniques
and expertise in analytical chemistry, and more particularly in
mass spectrometry, available at the Max Mousseron Institute of
Biomolecules4 and the Physical Measurement Laboratory5.
ATB-Discover will accelerate the identification
of active antimicrobial molecules in bacterial extracts at
DEINOVE:
- Better detection of molecules of
interest based on increased sensitivity during analysis;
- Determination of the molecular
formula of each molecule of interest enabled by the extreme
precision of Ultra High Resolution;
- Rapid determination of structures
of unknown molecules using a dedicated software suite.
“ATB-Discover will strengthen our interactions
with highly qualified and internationally recognized scientists
from the University of Montpellier. It will allow us to develop and
implement innovative strategies using the most powerful
state-of-the-art technology. The identification of the molecule
responsible for the antimicrobial activity in an environment that
may contain several thousand molecules is certainly one of the most
complex steps in the process. There is no doubt that this project
will increase our capacity to discover active molecules and serve
our priority goal: to bring new therapies to
patients.”, explains
Georges GAUDRIAULT, Chief Scientific
Officer of DEINOVE.
“We are pleased to be able to rely on the
support of the European Union and the Occitania Region in the
implementation of the ATB-Discover project. This funding is
essential at a time when the world is more than ever driven by
biotechnology companies in the finding of new treatments for
multi-resistant bacteria”, adds Alexis
RIDEAU, Chief
Executive
Officer of
DEINOVE.
« The ATB-Discover project perpetuates a
long-standing scientific collaboration with DEINOVE. The backing of
the Occitania Region and the European Union has been decisive in
financing the human and material resources necessary for the rapid
progress of such ambitious research. The acquisition of very high
technology equipment represents a sustainable investment to develop
and promote a chemistry serving mankind and his environment within
the University of Montpellier”, says
Christine ENJALBAL, Professor at
the Max Mousseron
Institute of Biomolecules and Director of
the Physical Measurement Laboratory of the
University of
Montpellier.
ABOUT DEINOVE
DEINOVE is a French biotechnology company
pioneering the exploration of a new domain of life, unexplored at
99.9%: the “microbial dark matter”. By revealing the metabolic
potential of rare bacteria or still classified as uncultivable, it
tackles a global health and economic challenge: antimicrobial
resistance. The new therapies discovered and developed by DEINOVE
target superbugs (microbes that have become resistant to one or
more antimicrobials) that cause life-threatening infections which
are now spreading at high speed.
This breakthrough approach gave rise to one of
the world’s first specialized micro-biotechnology platforms and a
unique collection of nearly 10,000 rare strains and thousands of
bacterial extracts. Today, DEINOVE is conducting several
development programs, of which its first antibiotic candidate is
currently evaluated in a Phase II clinical trial in severe
Clostridioides difficile infections, one of the world’s first
emergencies. The Company has also developed new bacterial
micro-factories that address the other issue in the race against
antimicrobial resistance: the industrial production of these rare
and low concentrated compounds with often too complex chemical
structures to be generated by chemical synthesis.Located at the
heart of the Euromedecine park in Montpellier, DEINOVE has been
listed on EURONEXT GROWTH® (ALDEI – code ISIN FR0010879056) since
2010. The Company has over 50 employees and relies on a network of
world-class academic, technological, industrial and institutional
partners.
ABOUT IBMM
IBMM is a unique research laboratory in Europe
bringing together over 300 people from the University of
Montpellier (UM), the CNRS and the Advanced National School of
Chemistry in Montpellier (l’Ecole Nationale Supérieure de Chimie de
Montpellier) (ENSCM) carrying out research on living molecules
(biomolecules) and their roles in and effects on health and the
environment. This research at the interface of chemistry and
biology contributes to a better understanding of physiological and
physiopathological mechanisms as well as to the development of
innovative tools for health: new and more efficient treatments
(cancers, cardiovascular diseases, neurodegenerative diseases), new
medical devices, new cosmetic approaches and new diagnostic
systems. IBMM has contributed to the market approval of two drugs
and the creation of more than 8 companies.
ABOUT LMP
The LMP is a service laboratory whose mission is
to provide physico-chemical analyses to meet the needs of
researchers in extremely diverse fields, from organic chemistry to
biomolecules, the environment and health. This technological
platform of the University of Montpellier is an integral part of
the Analysis and Characterization Platform (PAC) of the Balard
Chemistry Pole (Pôle Chimie Balard), which provides academic and
private partners with high-performance high-tech equipment backed
by the expertise of dedicated technical staff. The LMP thus
possesses skills and know-how in the characterization of samples in
life chemistry. The analytical equipment, grouped in three
complementary departments (Liquid Nuclear Magnetic Resonance, Mass
Spectrometry and Elementary Analysis), allows access, according to
the needs of research projects, to the detection, identification,
structural characterization and quantification of organic molecules
and biomolecules of interest, whether they are synthesized or
naturally present in complex media (biological fluids, natural
extracts). The LMP is able to answer many multidisciplinary
analytical questions at the biology-health and agronomy-ecology
interface.
CONTACTS
InvestorsMario AlcarazChief Financial and Administrative Officer+33
(0)4 48 19 01 00ir@deinove.comMediaATCG Partners – Marie PUVIEUX+33
(0)9 81 87 46 72 / +33 (0)6 10 54 36
72communication@deinove.com |
|
1https://urlz.fr/fZOk 2https://urlz.fr/fZOl 3
https://muse.edu.umontpellier.fr4 https://ibmm.umontpellier.fr5
https://lmp.edu.umontpellier.fr